{"entity":{"id":"adicet-bio","kind":"company","name":"Adicet Bio","aka":[],"tldr":"Adicet makes off-the-shelf immune cell therapies from donor gamma delta T cells, a rarer type of T cell. Its lead programme is now aimed at lupus and other autoimmune diseases, with a prostate cancer candidate expected to enter the clinic in late 2026.","summary":"Adicet Bio is a clinical-stage company developing allogeneic gamma delta T-cell therapies engineered with chimeric antigen receptors. Lead product prulacabtagene leucel (prula-cel, formerly ADI-001) is an allogeneic gamma delta CAR T candidate now developed primarily in autoimmune disease (lupus nephritis, systemic lupus erythematosus, systemic sclerosis, vasculitis and rheumatoid arthritis), with a phase 1 update and pivotal trial planning under way in 2026 after FDA alignment on outpatient dosing. In oncology, ADI-212 is a preclinical candidate for metastatic castration-resistant prostate cancer with a regulatory filing planned for the third quarter of 2026 and enrolment expected in the fourth quarter. Adicet is also building an in vivo CAR T platform for haematological malignancies and solid tumours. It completed a one-for-16 reverse stock split in December 2025 and trades on Nasdaq as ACET.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.adicetbio.com/"},{"label":"Q2 2026 results (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000049/acet-ex99_1.htm"},{"label":"January 2026 corporate update (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1720580/000119312526005486/acet-ex99_1.htm"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-t","in-vivo-car-t"],"targets":[],"drugs":["adi-270"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Pipeline is now led by autoimmune indications; oncology exposure is ADI-212 (prostate) and an in vivo CAR T platform. No funding round sourced."],"hq":"Redwood City, CA","country":"US","companyType":"cell-therapy","website":"https://www.adicetbio.com/","ticker":"ACET","stage":"public","investors":[],"funding":[]},"route":"/companies/adicet-bio/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"drug":[{"id":"adi-270","kind":"drug","name":"ADI-270","route":"/drugs/adi-270/"}]}}